Pre-earnings brief
Reports
Thu, Oct 29, 2026
Est. EPS
—
Est. revenue
—
Implied move
±10.8%
EPS beat rate
50%
Bio-Rad Laboratories, Inc. is a key player in the health care sector, specializing in life sciences tools and services. The company provides essential products for research and clinical diagnostics, making it significant in advancing health care solutions.
Last quarter
In Q2 2026, Bio-Rad reported an EPS of $2.62, surpassing estimates by nearly 12%. However, the stock saw a slight decline the following day.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
+10.95%
Avg 1-day reaction
-1.18%
Investors are cautiously optimistic ahead of the earnings report, particularly after the recent EPS beat, but uncertainty remains due to mixed historical performance.
Bull case
If Bio-Rad continues to show strong EPS growth and revenue increases, it could signal robust demand for its products, driving the stock higher.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to further stock declines, especially given its recent mixed results.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
The EPS figure will be critical in determining whether the company can maintain its growth trajectory and satisfy investor expectations.
Q2
What insights can management provide on revenue growth?
Understanding revenue growth will help gauge the demand for Bio-Rad's products and its competitive positioning in the market.
Est. EPS
—
Est. Rev
—
Impl. Move
±6.7%
Why consensus could be wrong
The Street may underestimate Bio-Rad's ability to leverage recent product innovations to drive revenue growth, especially in emerging markets.
Supporting evidence
The recent EPS beat suggests stronger than expected demand for Bio-Rad's products.
Options pricing indicates a significant expected move, which may reflect underlying confidence in the company's performance.
Key risk
If the company reports revenue growth exceeding 10%, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Bio-Rad can sustain its recent growth momentum amidst competitive pressures and economic conditions.
Bull confirmed if
An EPS of $2.75 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $2.30 would signal potential issues in demand or profitability.
What the market is pricing for the move.
Implied Move
±10.2%
Historical Avg
±1.6%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±10.8% while BIO has averaged ±1.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
30.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.7%, with a raw directional average of -0.1% (roughly flat historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
91.55%
of float
Insider
16.41%
of float
Holders
529
institutions
Top Holders· as of Jun 2026
First Eagle Investment Management, LLC
2,606,219 sh · $958.9M
12.02%
0.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Bio-Rad beats expectations, history suggests the stock could see a modest decline initially, but it may rally over the following days as confidence builds.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss could lead to a decline in the stock price, with history suggesting an average drop of around 0.97% following such outcomes.
The lines on the call that would change the story.
Blackrock Inc.
1,698,929 sh · $625.1M
7.84%
1.1%
Dimensional Fund Advisors LP
944,548 sh · $347.5M
4.36%
-13.3%
Vanguard Capital Management LLC
826,972 sh · $304.3M
3.81%
-0.5%
Vanguard Portfolio Management LLC
816,198 sh · $300.3M
3.77%
-1.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.